The accelerated approval of #lecanemab is welcome news for the millions living with #Alzheimers, but we have more to do. Drugs will only be beneficial if the right ones are given to the right patient at the right time, and for that we need new #biomarkers. bit.ly/3XeTUg2
1
7
13
4K
1
Download Image
@TheADDF We need more safer AD drugs show higher efficacy, easy to administer and cheaper price for AD patients globally.